Climb Bio (CLYM) Expected to Announce Earnings on Thursday

Climb Bio (NASDAQ:CLYM - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Climb Bio to post earnings of ($0.15) per share for the quarter.

Climb Bio Price Performance

Climb Bio stock traded up $0.02 during mid-day trading on Friday, reaching $1.30. The stock had a trading volume of 213,407 shares, compared to its average volume of 390,341. Climb Bio has a fifty-two week low of $1.20 and a fifty-two week high of $11.55. The company has a 50-day simple moving average of $1.61. The stock has a market cap of $87.39 million, a price-to-earnings ratio of -0.61 and a beta of -0.19.

Analysts Set New Price Targets

Several brokerages recently issued reports on CLYM. Leerink Partnrs raised Climb Bio to a "strong-buy" rating in a research report on Monday, December 2nd. Leerink Partners began coverage on Climb Bio in a research report on Monday, December 2nd. They set an "outperform" rating and a $10.00 target price on the stock.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.